INDIANAPOLIS, July 19, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 study for baricitinib were published by The Lancet. The study, the first completed Phase 2 study of a JAK inhibitor in SLE, showed that a statistically …
Tag Archives: baricitinib
July, 2018
June, 2018
-
4 June
FDA Approves Olumiant for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
INDIANAPOLIS, June 1, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation(NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved the 2-mg dose of OLUMIANT® (baricitinib), a once-daily oral medication for the treatment of adults with moderately-to-severely active rheumatoid arthritis (RA) who have had an inadequate response to one or …
April, 2018
-
25 April
FDA Committee Recommends Approval of Baricitinib for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis
INDIANAPOLIS, April 23, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis …
April, 2017
-
14 April
Lilly and Incyte Announce FDA Fails to Approve Baricitinib for Rheumatoid Arthritis
INDIANAPOLIS–(BUSINESS WIRE)–Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA). The …
January, 2017
-
16 January
FDA Extends Review Period for Investigational Rheumatoid Arthritis Drug Baricitinib
INDIANAPOLIS, Jan. 13, 2017 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib, a once-daily oral medication for the treatment of moderate …
October, 2015
-
14 October
Lilly and Incyte’s Oral RA Drug Demonstrates Superiority to Adalimumab in Phase III Trial
INDIANAPOLIS, Oct. 14, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis. The study met its primary objective of demonstrating superiority compared to placebo after …